公开(公告)号：US20210101902A1

公开(公告)日：2021-04-08

申请号：US17124346

申请日：2020-12-16

Applicant: NOVARTIS AG

Inventor： Phillip ALPER ,  Jonathan DEANE ,  Songchun JIANG ,  Tao JIANG ,  Thomas KNOEPFEL ,  Pierre-Yves MICHELLYS ,  Daniel MUTNICK ,  Wei PEI ,  Peter SYKA ,  Guobao ZHANG ,  Yi ZHANG

IPC: C07D471/04 ,  A61P17/06 ,  A61P1/16 ,  A61P37/06 ,  A61P19/02 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06

Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.

公开(公告)号：US20240376099A1

公开(公告)日：2024-11-14

申请号：US18678198

申请日：2024-05-30

Applicant: Novartis AG

Inventor： Phillip ALPER ,  Jonathan DEANE ,  Songchun JIANG ,  Tao JIANG ,  Thomas KNOEPFEL ,  Pierre-Yves MICHELLYS ,  Daniel MUTNICK ,  Wei PEI ,  Peter SYKA ,  Guobao ZHANG ,  Yi ZHANG

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  A61P1/16 ,  A61P17/06 ,  A61P19/02 ,  A61P37/06

Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.

公开(公告)号：US20190211009A1

公开(公告)日：2019-07-11

申请号：US16330820

申请日：2017-09-06

Applicant: Novartis AG

Inventor： Phillip Alper ,  Jonathan DEANE ,  Songchun JIANG ,  Tao JIANG ,  Thomas KNOEPFEL ,  Pierre-Yves MICHELLYS ,  Daniel MUTNICK ,  Wei PEI ,  Peter SYKA ,  Guobao ZHANG ,  YI ZHANG

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/541 ,  A61K45/06 ,  A61P37/06 ,  A61P19/02 ,  A61P17/06 ,  A61P1/16

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  A61P1/16 ,  A61P17/06 ,  A61P19/02 ,  A61P37/06

Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.

公开(公告)号：US20240141022A1

公开(公告)日：2024-05-02

申请号：US18396301

申请日：2023-12-26

Applicant: Novartis AG

Inventor： Jonathan DEANE ,  Yaiza DIAZ-DE-DURANA ,  Michael DIDONATO ,  Christophe FILIPPI ,  Glen SPRAGGON

IPC: C07K16/10 ,  A61K38/20 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C07K14/55 ,  C07K19/00 ,  C12N5/071 ,  C12N5/0783

CPC classification number: C07K16/1027 ,  A61K38/2013 ,  A61K39/3955 ,  A61K47/6801 ,  A61P35/00 ,  C07K14/55 ,  C07K19/00 ,  C12N5/0636 ,  C12N5/0682 ,  A61K45/06

Abstract: The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and produceability over recombinant human IL2 formulations such as Proleukin®.

公开(公告)号：US20230053449A1

公开(公告)日：2023-02-23

申请号：US17289058

申请日：2019-10-30

Applicant: NOVARTIS AG

Inventor： Lisa BARNETT ,  Steven BENDER ,  Alex Cortez ,  Sarah COX ,  Jonathan DEANE ,  Scott Martin GLASER ,  Ben WEN ,  Tom Yao-Hsiang WU

IPC: A61K47/68 ,  C07K16/28 ,  A61P35/00

Abstract: Provided herein are antibodies to DC-SIGN, conjugates of DC-SiGN antibodies, and DC-SiGN antibody fusion proteins and the use of such antibodies, conjugates, and fusion proteins for the treatment of diseases such as cancer.